Is uniQure N.V. (QURE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 7.4% / 30% | 41.3% / 30% | 0.7% / 30% | 78.97% / 5% | ✗ NOT HALAL |
| DJIM | 7.4% / 33% | 41.3% / 33% | 0.7% / 33% | 78.97% / 5% | ✗ NOT HALAL |
| MSCI | 11.9% / 33% | 66.0% / 33% | 1.1% / 33% | 78.97% / 5% | ✗ NOT HALAL |
| S&P | 7.4% / 33% | 41.3% / 33% | 0.7% / 33% | 78.97% / 5% | ✗ NOT HALAL |
| FTSE | 11.9% / 33% | 66.0% / 33% | 1.1% / 50% | 78.97% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -900.9% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -207.1% | |
| Return on Assets (ROA) | -16.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$178M |
| Free Cash Flow | -$178M |
| Total Debt | $63M |
| Debt-to-Equity | 269.8 |
| Current Ratio | 10.4 |
| Total Assets | $825M |
Price & Trading
| Last Close | $15.60 |
| 50-Day MA | $19.94 |
| 200-Day MA | $25.13 |
| Avg Volume | 3.3M |
| Beta | 0.8 |
|
52-Week Range
$7.76
| |
About uniQure N.V. (QURE)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is uniQure N.V. (QURE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), uniQure N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is uniQure N.V.'s debt ratio?
uniQure N.V.'s debt ratio is 7.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 11.9%.
What are uniQure N.V.'s key financial metrics?
uniQure N.V. has a market capitalization of $924M, and revenue of $16M. Return on equity stands at -207.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.